Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 8, 2010

University of Cardiff Spin-Out to Develop Cell-Based Cartilage-Replacement Therapy

  • Progenteq has been spun out from Cardiff University to develop a cell-based cartilage-replacement therapy. The company has been set up by Fusion IP, a university commercialization company that has exclusive rights to 100% of university-owned research generated at Cardiff University and the The University of Sheffield.

    The cartilage-replacement technology exploits a defined population of articular cartilage cells that Fusion claims display stem cell like properties and can be expanded ex vivo to generate large quantities of cartilage. Progenteq hopes to develop these cells as a stored bank of material for allogeneic cartilage-replacement therapy in patients with acute injuries.

    The company suggests that allogeneic implants would be more cost-effective than autologous approaches requiring the expansion of cartilage cells derived from individual patients. It also believes a cartilage cell bank could pave the way for new treatments against degenerative disorders such as osteoarthritis.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »